Contrasting Imris (OTCMKTS:IMRSQ) and Tandem Diabetes Care (NASDAQ:TNDM)

Imris (OTCMKTS:IMRSQ) and Tandem Diabetes Care (NASDAQ:TNDM) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for Imris and Tandem Diabetes Care, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Imris	0	0	0	0	0.00
Tandem Diabetes Care	1	10	8	2	2.52

Tandem Diabetes Care has a consensus target price of $29.89, indicating a potential upside of 133.19%. Given Tandem Diabetes Care’s stronger consensus rating and higher probable upside, analysts clearly believe Tandem Diabetes Care is more favorable than Imris.

Valuation & Earnings

This table compares Imris and Tandem Diabetes Care”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Imris	N/A	N/A	N/A	N/A	N/A
Tandem Diabetes Care	$1.01 billion	0.87	-$204.71 million	($1.40)	-9.16

Imris has higher earnings, but lower revenue than Tandem Diabetes Care.

Profitability

This table compares Imris and Tandem Diabetes Care’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Imris	N/A	N/A	N/A
Tandem Diabetes Care	-9.20%	-53.88%	-7.88%

Summary

Tandem Diabetes Care beats Imris on 5 of the 8 factors compared between the two stocks.

About Imris

IMRIS Inc. designs, manufactures, and sells image-guided therapy solutions worldwide. The company offers VISIUS Surgical Theatres, a surgical environment that provides intraoperative vision to clinicians to assist in decision-making and enhance precision in treatment. Its VISIUS Surgical Theatre incorporates magnetic resonance imaging, computed tomography, and fluoroscopy into multi-purpose surgical suites to provide intraoperative imaging for specific medical applications by bringing advanced imaging into the operating room (OR). The company sells the VISIUS Surgical Theatres to hospitals that deliver clinical services to patients in the neurosurgical, spinal, cerebrovascular, and cardiovascular markets. It also provides service and extended maintenance contracts, and accessories and disposables. The company was founded in 2005 and is based in Winnipeg, Canada.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.